Liquid allergy vaccine formulation for oromucosal administration

A technology of oral mucosa, liquid preparations, applied in the field of allergic reaction vaccine preparations

Inactive Publication Date: 2007-10-03
ALK ABELLO SA
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This may be advantageous, for example, in the stomach or intestinal tract, where there is a risk of acid and enzymatic degradation, respectively

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liquid allergy vaccine formulation for oromucosal administration

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0074] Example 1: Sublingual treatment of mice with a liquid formulation of aluminum hydroxide and the gross allergen PhleumPratense (Phl p)

[0075] treatment method

[0076] Mice received a treatment regimen consisting of sensitization consisting of three intraperitoneal (i.p.) injections and SLIT treatment consisting of once daily administration of a liquid formulation with one of the following formulations five days a week over a six-week period: 1) 5,000 SQ-u Phl p with no aluminum hydroxide (7 mice); 2) 5,000 SQ-u with aluminum hydroxide (Alhydrogel(R) 1.3%) at a concentration corresponding to 1.25 mg Al / ml (8 mice); 3) 500 SQ-u and aluminum hydroxide (Alhydrogel(R) 1.3%) at a concentration corresponding to 1.25 mg Al / ml (10 mice); and 4) no pasture allergen and no aluminum hydroxide (10 mice). For SLIT treatment, each dose included a volume of 5 μl of liquid formulation, ie each dose included an amount of 1.25 / 20 mg Al. For intraperitoneal injection, each dose include...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

Use of a composition comprising an allergen and an adjuvant selected from the group consisting of oxygen-containing metal salts for the manufacture of a liquid formulation for preventing or treating allergy in a subject by oromucosal administration, and a method of preventing and treating allergy in a subject by oromucosal administration of the said liquid formulation.

Description

technical field [0001] The present invention relates to anaphylaxis vaccine formulations for oromucosal administration. Background of the invention [0002] Allergic reactions are a major health problem in countries adopting a western lifestyle. In addition, the prevalence of allergic diseases is increasing in these countries. Although in general, anaphylaxis is not considered a life-threatening condition, asthma is responsible for a large number of deaths each year. The prevalence of the disorder in about 30% of adolescents results in a significant reduction in quality of life, workday and money, and constitutes a major type of health problem in the Western world. [0003] Anaphylaxis is a complex disease. Allergic events are caused by a variety of factors, including an individual's susceptibility determined by the not-well-understood interplay of several genes. Another important factor is exposure to allergens above a certain threshold. Several environmental factors m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/35A61K39/39
CPCA61K9/006A61K39/36A61K2039/542A61K2039/55505A61P27/14A61P37/06A61P37/08A61P43/00A61K39/39
Inventor J·布里莫奈斯J·基尔德斯加德
Owner ALK ABELLO SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products